Table 2.
Baseline to week 12 endpoint changes in EORTC QLQ-C30 scores by age groups
|
Ipilimumab plus gp100 |
Ipilimumab plus gp100 |
Ipilimumab Alone |
Ipilimumab Alone |
|
|---|---|---|---|---|
| < 65 years |
≥ 65 years |
< 65 years |
≥ 65 years |
|
| (N = 170) | (N = 66) | (N = 59) | (N = 26) | |
| Physical function |
−6.2 |
−9.5 |
−4.3 |
−9.3 |
| Role function |
−9.8 |
−11.7 |
−11 |
−12.9 |
| Emotional function |
−0.8 |
−6.2 |
−2.2 |
−9.3 |
| Cognitive function |
−3.9 |
−4.7 |
−3.6 |
−8.8 |
| Social function |
−5.4 |
−7.4 |
−6 |
−12.3 |
| Global health |
−6.5 |
−12.1 |
−6 |
−17 |
| Fatigue |
9 |
14.2 |
12.4 |
12.1 |
| Nausea/vomiting |
5.3 |
7.3 |
4.9 |
3.1 |
| Pain |
7.2 |
6.4 |
10 |
7.4 |
| Dyspnea |
2 |
8.1 |
2.1 |
12.5 |
| Sleep disturbance |
5 |
10.4 |
8.8 |
12.9 |
| Appetite loss |
9.4 |
9.6 |
12.9 |
11.7 |
| Constipation |
3.8 |
6 |
2.3 |
−0.4 |
| Diarrhea | 6.2 | 7.7 | 7.7 | 13.5 |